26 Feb 2024 , 11:37 AM
From February 20 to 23, 2024, the US FDA performed a Pre-Approval Inspection (PAI) at Piramal Pharma Limited’s Lexington, USA, plant in order to examine one of the products that is anticipated to be produced there.
A Form-483 with two observations was issued following the examination. The site’s business continuity or compliance with compliance standards are not at risk as a result of the observations. The Company is getting ready to submit to the US FDA within the allotted timeframe a comprehensive response to the aforementioned observations.
The Company is still dedicated to upholding the highest compliance standards, and it will collaborate closely with the agency to thoroughly address each and every observation.
Piramal Pharma Limited’s shares traded at ₹135.50 down 0.60% from previous close of ₹136.30.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
